Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Worst Biotech CEOs 2017
Adam's Take

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

By Adam Feuerstein

Best Biotech CEOs 2017
Adam's Take

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Why Gilead’s new CEO is a solid choice to help the biotech grow again

By Adam Feuerstein

Adam's Take

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

By Adam Feuerstein

Adam's Take

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

By Adam Feuerstein

Adam's Take

If biotech stock values are down, why isn’t M&A picking up?

By Adam Feuerstein

Stock market dystopia
Adam's Take

Biotech is looking woozy: ferocious selling and a sense of foreboding

By Adam Feuerstein

Adam's Take

Amarin, Vascepa, and mineral oil. There is more to consider with this fish-oil drug story

By Adam Feuerstein

Metastatic Melanoma Cells
Adam's Take

Skin cancer immunotherapy could have potential but don’t hang hopes on new data

By Adam Feuerstein

Pick A Card
Adam's Take

Acadia Pharma conjures black magic to spin a failed depression drug trial

By Adam Feuerstein

Squamous_carcinoma_lung_cytology
Adam's Take

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

By Adam Feuerstein

Adam's Take

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

By Adam Feuerstein

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Fish oil pills on pink
Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Fish oil capsules
Adam's Take

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

By Adam Feuerstein

Metastatic Melanoma Cells
Adam's Take

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

By Adam Feuerstein

Sickle Cell meds illo
Adam's Take

Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think

By Adam Feuerstein

Adam's Take

Amgen emerges as new multiple myeloma drug player, threatening Bluebird, Celgene

By Adam Feuerstein

Adam's Take

Answers to biotech’s burning questions for 2018: winners, floppers, and procrastinators

By Adam Feuerstein

Liver illustration
Adam's Take

Can plastic tubes stop livers from failing? Unlikely, but a biotech keeps trying

By Adam Feuerstein

Adam's Take

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

By Adam Feuerstein

Business

Investors are pouring more money into biotech funds, and stocks are responding

By Adam Feuerstein

Adam's Take

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

By Adam Feuerstein

Hepatitis Drugs
Adam's Take

Gilead Sciences’ board is looking for a new CEO. Here’s a list of possible contenders

By Adam Feuerstein

Adam's Take

Gilead’s golden era ends with the executive departures of ‘The Johns’

By Adam Feuerstein

Adam's Take

ResTORbio drug study results weaken under scrutiny

By Adam Feuerstein

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy